Global Pediatric Nasal Cannula Market - 2022-2029

Market Overview

The global pediatric nasal cannula market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

A nasal cannula is a device used to deliver supplemental oxygen or increased airflow to a patient or person with trouble breathing.

Market Dynamics

The factors influencing the global pediatric nasal cannula market are the increasing demand for pediatric cannulas and the growing prevalence of breathing.

The increasing demand for pediatric nasal cannula is expected to drive the market growth

The high-flow nasal cannula (HFNC) is a new non-invasive ventilation therapy that appears to be well tolerated in children. Both pediatric and adult care settings have seen a significant increase in the use of HFNC recently. HFNC has been widely used in adult patients in recent decades. Acute hypoxemic respiratory failure, post-extubation support, preoxygenation before intubation or during bronchoscopy, postoperative respiratory failure, and acute pulmonary edema are indications from the evidence in adults. Patients with acute bronchiolitis have been included in many pediatric studies. Other indications, such as asthma, sleep apnea, pneumonia, critical patient transport, and postextubation respiratory support, have been investigated. Oxygen therapy with a heated, humidified high-flow nasal cannula (HHHFNC) provides warmed, humidified oxygen at flow rates that exceed minute volume requirements. High oxygen concentrations and positive intrathoracic airway pressure can be achieved with 1 to 2 L/kg/min flow rates. Since its introduction to neonatal intensive care over 20 years ago, HHHFNC therapy has become more widely used to help neonates, children, and adults with severe respiratory distress avoid intubation or reintubation. Nasal cannulas with smaller prongs are used for pediatric use, carrying 0.5-1 liter of oxygen per minute for neonates, 1-2 litre for infants, and 1-4 litre for older children. These pediatric nasal cannula devices are softer and gentler on infants' delicate facial skin. These devices are made of lightweight tubes that can easily be wrapped around the ears of the patients. The tube's one end is inserted into the nostrils, while the other is connected to the oxygen concentrator. There is a small chance that mucus will obstruct the airway.

The limitations associated with pediatric nasal cannula are expected to hamper the market

Nasal cannula pressure recordings are limited by obstruction of the tubing with secretions, mouth breathing (especially in children with adenoidal hypertrophy), and a possible increase in nasal resistance due to obstruction of the nares. Other drawbacks include the requirement for nasal patency and the unpredictability of fractional oxygen concentration in inspired gas with oral versus nasal breathing, with studies yielding mixed results. Nasal cannulas used at high flow rates for long periods can dry out the nasopharyngeal mucosa, so humidification of source oxygen is recommended. The high-flow nasal cannula was originally a three-channelled version of the conventional cannula that could deliver flows of up to 15 L/min, corresponding to an effective fractional concentration of oxygen in inspired gas of up to 50-70%. Hudson RCI manufactures this nasal cannula, also known as the Hudson nasal cannula. This is not to be confused with the heated high-flow nasal cannula (HFNC), which can deliver up to 60 L/min. of flow.

COVID-19 Impact Analysis

A time-limited trial of noninvasive ventilation (NIV) or high-flow nasal cannula (HFNC) oxygen is recommended for infants and children with COVID-19 and persistent respiratory failure despite conventional oxygen therapy who have no indicators for endotracheal intubation (AIIa). In infants and children with COVID-19, there is insufficient evidence to recommend either for or against the use of HFNC oxygen over NIV or NIV over HFNC oxygen. HFNC can provide a specific positive end-expiratory pressure, which strongly affects type I respiratory failure in mild to moderate cases. It can also deliver adequately warmed and humidified gas through the nasal pharynx, reducing the metabolic work required for gas conditioning. Furthermore, HFNC can help patients with acute respiratory failure avoid intubation and improve their clinical prognosis. Hence, covid-19 is expected to boost market growth.

Segment Analysis

Neonatal Nasal Cannula segment is expected to dominate the market growth

A nasal cannula is a thin, plastic tube with two small prongs that deliver oxygen directly into the nose. It's a type of respiratory support used in both adults and children. Breathing difficulties are one of the most common problems that premature babies face. A nasal cannula, ventilator-assisted breathing, and continuous positive airway pressure are just a few interventions to help babies breathe (CPAP). Nasal cannulas are used when a low flow, the low or medium concentration of oxygen is required, and the patient is in a stable state. Nasal cannulas are almost always used in the NICU to deliver warmed, humidified oxygen. They can help babies in two ways with the oxygen they deliver. First, as oxygen is blown into the nose, nasal cannulas apply a small amount of pressure, which can help babies' lungs stay inflated and remind them to breathe. Parents may refer to this as "flow" or a specific number of "litres." Second, they can deliver more oxygen than normal to help babies oxygenate their bodies. To increase flow, CPAP therapy is used. This is used instead of a nasal cannula in some babies. When a baby breathes in, the nasal cannula delivers a mixture of room air and oxygen. The oxygen concentration in the baby's lungs can vary from 21 percent to 100 percent. Larger babies may receive less oxygen at a lower concentration. To mix oxygen with room air, a special blender can be used. Compared to babies who receive CPAP, those given a nasal cannula may experience less gastric distension, be able to breast or bottle-feed more easily and benefit from the benefits of close physical contact with their parents.

Many companies manufacture neonatal nasal cannulas. For instance, Armstrong Medical manufactures fixation and securement options for the NeoFlow ultra-soft nasal high flow cannula are available. Fixation pads are made of hypoallergenic 3M Gentle Si Medical Acrylic Silicone tape, which is gentle on the baby's skin. The neonatal cannula comes in five sizes to accommodate flows ranging from 1 to 25 litres per minute in neonates and children.

Geographical Analysis

North America region is expected to hold the largest market share in the global pediatric nasal cannula market

The increasing demand for pediatric nasal cannula and the growing prevalence of respiratory problems are expected to drive this region's market growth.

Asthma is the most common chronic illness among children, affecting an estimated 6.1 million children under 18 in the United States, with 3.5 million having experienced an asthma attack or episode. Asthma affects approximately 5.1 million children under the age of 18. Compared to white children, black children are nearly three times more likely to have asthma. Male children are more likely than female children to suffer from asthma. Asthma affects approximately 8.4% of male children and 5.5 percent of female children. Moreover, the increasing number of key players in this region is also expected to drive market growth. For instance, Neotech products are designed and manufactured in the United States, with all materials sourced from North America. The company manufactures the RAM Cannula has soft, gently curved prongs for patient comfort. Its simple setup and flexible tubing help infants and children be in developmentally appropriate positions.

Competitive Landscape

The global pediatric nasal cannula market is moderate with mergers, acquisitions, and product launches. Some of the key players in the market are Flexicare Medical Limited, Salter Labs, DeVilbiss Healthcare LLC, Besmed Health Business Corp., Fisher & Paykel Healthcare Limited, Medin Medical Innovations GmbH, Teleflex Incorporated, GaleMed Corporation, Neotech Products, Hamilton Medical

Fisher & Paykel Healthcare Limited

• Overview: Fisher & Paykel Appliances Holdings Ltd is a major appliance company subsidiary of Haier, a Chinese multinational home appliance company. It is a New Zealand multinational corporation headquartered in East Tamaki. The company was founded in 1934.

• Product Portfolio: The Fisher & Paykel Healthcare Optiflow Junior 2 Nasal Interface is a non-sealing nasal interface designed to meet the flow requirements and anatomical features of neonates, infants, and children receiving high nasal flow (NHF) therapy. When a patient's cheeks are compressed, the Optiflow Junior 2 cannula uses Waveflex technology to allow for natural facial movement.